Thursday, October 15, 2015 | 8:00 AM - 5:00 PM
Speakers: Jonathan Braun (University of CaliforniaLos Angeles), Rudolph Clerval (Enterome), Stanislav Dusko Ehrlich (King's College London), Michael A. Fischbach (University of California, San Francisco), Andy Goodman (Yale School of Medicine), Randy Longman (Weill Cornell Medical College), Sarkis Mazmanian (California Institute of Technology), Paul O'Toole (University College Cork), R. Balfour Sartor (University of North Carolina School of Medicine)
In the human colon, the microbiome forms one of the densest bacterial ecosystems known in nature. This symposium will highlight recent research innovations and therapeutic applications from the microbiome with a focus on gut health.
Tuesday, October 27, 2015 | 8:00 AM - 5:00 PM
Speakers: Andras J. Bauer (Boehringer Ingelheim USA), Michael R. Jackson (Sanford Burnham Prebys Medical Discovery Institute), Jonathan A. Lee (Eli Lilly), Martin Main (AstraZeneca), Friedrich Metzger (F. Hoffmann-La Roche Ltd), Bruce A. Posner (University of Texas, Southwestern Medical Center), Aravind Subramanian (Broad Institute), Giulio Superti-Furga (Austrian Academy of Sciences), Susanne Swalley (Novartis Institutes for Biomedical Research)
This symposium aims to deepen our understanding of phenotypic drug discovery and to foster the exchange of ideas between industry-based and academic research scientists.
October 28 - 29, 2015
This 2-day colloquium will explore challenges surrounding pre-approval access to investigational medicines in a series of debates featuring prominent representatives of governments, pharmaceutical companies, patient groups, NGOs, and foundations.
Tuesday, December 8, 2015 | 8:30 AM - 5:00 PM
Speakers: David D'Alessio (University of Cincinnati), Richard DiMarchi (Indiana University), Keld Fosgerau (Zealand Pharma), Matthew Hayes (Perelman School of Medicine, University of Pennsylvania), George Holz (State University of New York), Lotte Knudsen (Novo Nordisk), Patrick Sexton (Monash University), Konrad Talbot (Cedars-Sinai Medical Center), Beat Jucker (GlaxoSmithKline)
GLP-1 receptor agonists have improved treatment options in type 2 diabetes, although realizing their promise in other areas remains challenging. This symposium highlights preclinical and clinical breakthroughs and opportunities for drug development.
Monday, February 22, 2016 | 9:00 AM - 5:00 PM
Speakers: Edward Lanphier (Sangamo BioSciences), Jane S Lebkowski (Asterias Biotherapeutics), Racheli Ofir (Pluristem Therapeutics Inc), Mahendra Rao (The New York Stem Cell Foundation Research Institute), John Sinden (ReNeuron), Kathleen Tsolkas (Janssen Research and Development)
Advances in gene editing cell have driven an explosion of pre-clinical cell based therapies. This event addresses the need to rethink clinical, regulatory & manufacturing approaches to accelerate the transition of drugs through the clinic.
September 30 - October 1, 2015
Keynote Speaker: Ian Ferguson (ARM), Christian Stammel (Wearable Technologies AG)
Speakers: Pam Baker (FierceBigData), Stan Berkow (Sense Health), Brian Bot (Sage Bionetworks), Michelle De Mooy (Consumer Privacy Project at Center for Democracy and Technology), Glen de Vries (Medidata), John Hixson (University of California at San Francisco), Julian Jenkins (GlaxoSmithKline), David C. Magnus (Stanford Center for Biomedical Ethics), Linda A. Malek (Moses and Singer, LLP), John Mastrototaro (Medtronic), Veena Misra (The NSF Nanosystems Engineering Research Center (NERC) for Advanced Self-Powered Systems of Integrated Sensors and Technologies (ASSIST) and North Carolina State University), Bernard Munos (FasterCures [a center of the Milken Institute]), Fiorenzo Omenetto (Tufts University), Aydogan Ozcan (UCLA and the Howard Hughes Medical Institute), Tomasz Sablinski (Transparency Life Sciences), Leonard Sacks (U.S. Food and Drug Administration), Pei Wang (Icahn School of Medicine at Mount Sinai)
Continuous health monitoring using wearable sensors, mobile devices, and apps is becoming a powerful tool for assessing critical physiological parameters. The vast accumulation of real-time biometric data obtained from these technologies may hold invaluable clues for treating some of the most devastating human diseases.
Tuesday, September 29, 2015 | 12:00 PM - 5:00 PM
Speakers: Samie R. Jaffrey (Weill Cornell Medical College), Amy E. Palmer (University of Colorado)
This symposium features state of the art chemical tools and imaging strategies for metal ions, redox signaling species, and metabolites in the cell, cellular delivery and targeting approaches, and their application to studying life processes.
Friday, September 18, 2015 | 8:30 AM - 5:00 PM
Speakers: George S. Bloom (University of Virginia), Peter Davies (Feinstein Institute for Medical Research), Marc I. Diamond (University of Texas Southwestern Medical Center), Michael Hutton (Eli Lilly and Company), Khalid Iqbal (New York State Institute for Basic Research in Developmental Disabilities), Magdalena J. Kiprowska (Hunter College and Graduate Center, CUNY), Hartmuth C. Kolb (Johnson & Johnson, Janssen R&D), Nicole Leclerc (Université de Montréal), Kun Ping Lu (Harvard Medical School), Natura Myeku (Taub Institute for Alzheimer's Disease Research, Columbia University), Richard M. Ransohoff (Biogen)
Speakers at this symposium will address novel tau-centered mechanisms of neurodegeneration and new therapeutic approaches for many devastating neurological disorders.
Wednesday, September 16, 2015 | 8:00 AM - 2:15 PM
Award Winner Bert Vogelstein (Johns Hopkins School of Medicine; Howard Hughes Medical Institute)
This symposium will honor Dr. Bert Vogelstein, the recipient of the 2015 Dr. Paul Janssen Award for Biomedical Research, in recognition of his role in characterizing the underlying mechanisms of cancer. Symposium registration is free. Advance registration is required.
Organizers: Walter Jessen (Covance Inc.), Robert Martone (St. Jude Children's Research Hospital), and Sonya Dougal (The New York Academy of Sciences)
Keynote Speaker: Niven R. Narain (Berg Pharma)
This eBriefing explores how big data and predictive knowledge are used to guide drug development and clinical trials.
Organizers: Howard Fillit (Alzheimer's Drug Discovery Foundation), Diana Shineman (Alzheimer's Drug Discovery Foundation), and Sonya Dougal (The New York Academy of Sciences)
This eBriefing explores related research in cancer and neurodegeneration and insights from cancer biology that may advance new therapeutic development for neurodegenerative diseases.
Edited by Ole Vang
(Roskilde University, Roskilde, Denmark) and John M. Pezzuto
(University of Hawaii at Hilo, Hilo, Hawaii)
Recent findings on the biological effects and therapeutic potential of resveratrol and its derivatives.
Organizers: Lydia Finley (Memorial Sloan-Kettering Cancer Center), Steven S. Gross (Weill Cornell Medical College), Costas A. Lyssiotis (Weill Cornell Medical College), and Sonya Dougal (The New York Academy of Sciences)
Keynote Speaker: Craig B. Thompson (Memorial Sloan-Kettering Cancer Center)
There is resurgent interest in cancer cell metabolism as researchers seek to understand how metabolic pathways are altered in cancer and how these alterations can be exploited for therapeutic gain. This eBriefing discusses advances in the field.
September 11, 2015
Understanding nutrition's impact on health requires an intricate knowledge of all the different systems within the human body. Learn how a systems approach to nutrition could change the field.
A recent conference held at the Academy asked a downright outrageous question: Can dementia be prevented by making changes to your diet? In this podcast we look at what the answers might be.
In the second of a two-part series, experts look at the links between health and nutrition. They examine everything from how nutrition impacts hospital stays, to cancer and aging, to developing food science innovations, and improving diet.
February 23, 2010
Researchers met to discuss advances in basic and translational research on metabotropic glutamate receptors, which are promising targets in drug discovery for CNS diseases and other illnesses.
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.
April 28, 2009
Protein kinases play a key role in almost every major pathway in eukaryotic cells. Structural approaches, including a new method called fragment-based drug design, are identifying potential targets against diseases including cancer.